Mairead McNamara, Senior Lecturer at University of Manchester and Honorary Consultant in Medical Oncology at The Christie NHS Foundation Trust, shared on X:
“Great to see more research in EP-NEC at the ASCO 2026.
Abstract 4004 was presented by Dr. Zhao.
Alveltamig, a trispecific T-cell engager targeting (DLL3/DLL3/CD3); refractory NEC (N=64) (mostly GI primaries);ORR 56.3% 30mg dose in DLL3 >/= 50%, Med OS 10.19 mo in 10mg dose, NR in 30mg dose.”
Other articles featuring Dr. Mairead on OncoDaily.
